IJMS | Free Full-Text | Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors | HTML
Mutations of the p53 Gene as a Prognostic Factor in Aggressive B-Cell Lymphoma | NEJM
Systematic identification of mutations and copy number alterations associated with cancer patient prognosis | eLife
TP53 alterations of hormone-naïve prostate cancer in the Chinese population | Prostate Cancer and Prostatic Diseases
TP53 mutations as potential prognostic markers for specific cancers: Analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database | bioRxiv
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma
Zinc shapes the folding landscape of p53 and establishes a pathway for reactivating structurally diverse cancer mutants | eLife
IJMS | Free Full-Text | Do Mutations Turn p53 into an Oncogene? | HTML
TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection - eBioMedicine
The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density | npj Breast Cancer
Mutant p53 Drives Cancer Metastasis via RCP-Mediated Hsp90α Secretion - ScienceDirect
Implications of driver genes associated with a high tumor mutation burden identified using next‑generation sequencing on immunotherapy in hepatocellular carcinoma
Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function | PNAS
Cancers | Free Full-Text | TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes | HTML
Mutant p53 elicits context-dependent pro-tumorigenic phenotypes | Oncogene
Frontiers | Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies
Disarming mutant p53 oncogenic function - ScienceDirect
Frontiers | Prevalence of the Brazilian TP53 Founder c.1010G>A (p.Arg337His) in Lung Adenocarcinoma: Is Genotyping Warranted in All Brazilian Patients?
Five‐year overall survival rate in patients with oncomorphic and... | Download Scientific Diagram
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others | Nature Reviews Clinical Oncology
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma - Journal of Thoracic Oncology
Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes | Oncogene
